The potential and rationale for COX-2 inhibitors in lung cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 6, Issue 3, 2006, Pages 209-220

  Krysan, Kostyantyn ^a   Reckamp, Karen L ^a,b   Sharma, Sherven ^b   Dubinett, Steven M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

COX inhibitors; COX 2; Cyclooxygenase; Lung cancer

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE 3; CYTOKINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETORICOXIB; INDOMETACIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 8 ANTIBODY; LUMIRACOXIB; MITOGEN ACTIVATED PROTEIN KINASE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PARECOXIB; PROSTAGLANDIN E2; ROFECOXIB; SULINDAC; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VALDECOXIB;

ANALGESIA; ANGIOGENESIS; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER PREVENTION; CANCER RESISTANCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL GROWTH; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; IMMUNOREGULATION; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LYMPHOCYTE FUNCTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; LUNG NEOPLASMS; MAP KINASE KINASE 2; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDINS; RECEPTORS, PROSTAGLANDIN;

EID: 33744471666     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152006776930882     Document Type: Review

References (183)

1. Jemal, A.; Murray, T.; Samuels, A.; Ghafoor, A.; Ward, E.; Thun, M.J. Cancer statistics, 2003. CA Cancer J. Clin., 2003, 53, 5.
2. Dy, G.K.; Adjei, A.A. Novel targets for lung cancer therapy: Part I. J. Clin. Oncol., 2002, 20, 2881.
3. Dy, G.K.; Adjei, A.A. Novel targets for lung cancer therapy: Part II. J. Clin. Oncol., 2002, 20, 3016.
4. Hirsch, F.R.; Franklin, W.A.; Bunn, P.A. Jr. Expression of target molecules in lung cancer: Challenge for a new treatment paradigm. Semin. Oncol., 2002, 29, 2.
5. Dubinett, S.; Sharma, S.; Huang, M.; Dohadwala, M.; Pold, M.; Mao, J. Cyclooxygenase-2 in lung cancer. In Prog. Exp. Tumor Res., Bertino, J.R., Ed.; Basel Karger: Basel, 2003; pp. 138-162.
6. Dannenberg, A.J.; Subbaramaiah, K. Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell, 2003, 4, 431.
7. Herschman, H. Review: Prostaglandin synthase 2. Biochim. Biophys. Acta, 1996, 1299, 125.
8. Katori, M.; Majima, M. Cyclooxygenase-2: Its rich diversity of roles and possible application of its selective inhibitors. Inflamm. Res., 2000, 49, 367.
9. Burr, G.O.; Burr, M.M. On the nature and role of the fatty acids essential in nutrition. J. Biol. Chem., 1930, 86, 587.
10. Kurzrok, R.; Lieb, C.C. Biochemical studies of human semen. II. The action of semen on the human uterus. Proc. Soc. Exp. Biol. Med., 1930, 28, 268.
11. von Euler, U.S. An adrenaline-like action in extracts from the prostatic and related glands. J. Physiol., 1934, 81, 102.
12. von Euler, U.S. On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). J. Physiol., 1936, 88, 213.
13. Bergström, S.; Danielsson, H.; Samuelsson, B. The enzymatic formation of prostaglandin E2 from arachidonic acid prostaglandins and related factors 32. Biochim. Biophys. Acta, 1964, 90, 207.
14. Funk, C.D. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science, 2001, 294, 1871.
15. Malkowski, M.G.; Ginell, S.L.; Smith, W.L.; Garavito, R.M. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science, 2000, 289, 1933.
16. FitzGerald, G.A. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov., 2003, 2, 879.
17. Dubois, R.N.; Abramson, S.B.; Crofford, L.; Gupta, R.A.; Simon, L.S.; Van De Putte, L.B.; Lipsky, P.E. Cyclooxygenase in biology and disease. FASEB J., 1998, 12, 1063.
18. Smith, W.L.; DeWitt, D.L.; Garavito, R.M. Cyclooxygenases: Structural, cellular, and molecular biology. Annu. Rev. Biochem., 2000, 69, 145.
19. Chandrasekharan, N.V.; Dai, H.; Roos, K.L.; Evanson, N.K.; Tomsik, J.; Elton, T.S.; Simmons, D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc. Natl. Acad. Sci. USA, 2002, 99, 13926.
20. Ishihara, O.; Sullivan, M.H.; Elder, M.G. Differences of metabolism of prostaglandin E2 and F2 alpha by decidual stromal cells and macrophages in culture. Eicosanoids, 1991, 4, 203.
21. Aoyama, T.; Yui, Y.; Morishita, H.; Kawai, C. Prostaglandin 12 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectons. Circulation, 1990, 81, 1784.
22. Kliewer, S.A.; Lenhard, J.M.; Willson, T.M.; Patel, I.; Morris, D.C.; Lehmann, J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell, 1995, 83, 813.
23. Riedl, K.; Krysan, K.; Pold, M.; Dalwadi, H.; Heuze-Vourch, N.; Dohadwala, M.; Liu, M.; Cui, X.; Figlin, R.; Mao, J.T.; Strieter, R.; Sharma, S.; Dubinett, S.M. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat., 2004, 7, 169.
24. Sheng, H.; Shao, J.; Washington, M.K.; DuBois, R.N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem., 2001, 276, 18075.
25. Krysan, K.; Reckamp, K.; Sharma, S.; Dohadwala, M.; Dubinett, S. PGE2 activates MAPK/Erk pathway in non-small cell lung cancer cells in an EGF receptor-independent manner. Cancer Res., 2005, 65, 6275.
26. Pai, R.; Soreghan, B.; Szabo, I.L.; Pavelka, M.; Baatar, D.; Tarnawski, A.S. Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med., 2002, 8, 289.
27. Tsujii, M.; Dubois, R. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell, 1995, 83, 493.
28. Bhattacharya, M.; Peri, K.G.; Almazan, G.; Ribeiro-da-Silva, A.; Shichi, H.; Durocher, Y.; Abramovitz, M.; Hou, X.; Varma, D.R.; Chemtob, S. Nuclear localization of prostaglandin E2 receptors. Proc. Natl. Acad. Sci. USA, 1998, 95, 15792.
29. Breyer, R.M.; Kennedy, C.R.; Zhang, Y.; Breyer, M.D. Structure-function analyses of eicosanoid receptors. Physiologic and therapeutic implications. Ann. N Y Acad. Sci., 2000, 905, 221.
30. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol., 1971, 231, 232.
31. Smith, W.L.; DeWitt, D.L.; Garavito, R.M. Cyclooxygenases: Structural, cellular, and molecular biology. Annu. Rev. Biochem., 2000, 69, 145.
32. Loll, P.J.; Picot, D.; Garavito, R.M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol., 1995, 2, 637.
33. Kurumbail, R.G.; Stevens, A.M.; Gierse, J.K.; McDonald, J.J.; Stegeman, R.A.; Pak, J.Y.; Gildehaus, D.; Miyashiro, J.M.; Penning, T.D.; Seibert, K.; Isakson, P.C.; Stallings, W.C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature, 1996, 384, 644.
34. Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C.T.; Scozzafava, A.; Klebe, G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: New pharmacological opportunities due to related binding site recognition. J. Med. Chem., 2004, 47, 550.
35. Tegeder, I.; Pfeilschifter, J.; Geisslinger, G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J., 2001, 15, 2057.
36. Wick, M.; Hurteau, G.; Dessev, C.; Chan, D.; Geraci, M.W.; Winn, R.A.; Heasley, L.E.; Nemenoff, R.A. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol. Pharmacol., 2002, 62, 1207.
37. Huang, C.; Ma, W.Y.; Hanenberger, D.; Cleary, M.P.; Bowden, G.T.; Dong, Z. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J. Biol. Chem., 1997, 272, 26325.
38. Dogne, J.M.; Supuran, C.T.; Pratico, D. Adverse cardiovascular effects of the coxibs. J. Med. Chem., 2005, 48, 2251.
39. Fitzgerald, G.A. Coxibs and cardiovascular disease. N. Engl. J. Med., 2004, 351, 1709.
40. Soslow, R.A.; Dannenberg, A.J.; Rush, D.; Woemer, B.M.; Khan, K.N.; Masferrer, J.; Koki, A.T. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer, 2000, 89, 2637.
41. Yip-Schneider, M.T.; Barnard, D.S.; Billings, S.D.; Cheng, L.; Heilman, D.K.; Lin, A.; Marshall, S.J.; Crowell, P.L.; Marshall, M.S.; Sweeney, C.J. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis, 2000, 21, 139.
42. Kirschenbaum, A.; Liu, X.; Yao, S.; Levine, A.C. The role of cyclooxygenase-2 in prostate cancer. Urology, 2001, 58, 127.
43. Fujita, T.; Matsui, M.; Takaku, K.; Uetake, H.; Ichikawa, W.; Taketo, M.M.; Sugihara, K. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res., 1998, 58, 4823.
44. Shamma, A.; Yamamoto, H.; Doki, Y.; Okami, J.; Kondo, M.; Fujiwara, Y.; Yano, M.; Inoue, M.; Matsuura, N.; Shiozaki, H.; Monden, M. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin. Cancer Res., 2000, 6, 1229.
45. Chan, G.; Boyle, J.O.; Yang, E.K.; Zhang, F.; Sacks, P.G.; Shah, J.P.; Edelstein, D.; Soslow, R.A.; Koki, A.T.; Woerner, B.M.; Masferrer, J.L.; Dannenberg, AJ. Cyclooxygenase-2 expression is upregulated in squarnous cell carcinoma of the head and neck. Cancer Res., 1999, 59, 991.
46. Hida, T.; Yatabe, Y.; Achiwa, H.; Muramatsu, H.; Kozaki, K.; Nakamura, S.; Ogawa, M.; Mitsudomi, T.; Sugiura, T.; Takahashi, T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res., 1998, 58, 3761.
47. Wolff, H.; Saukkonen, K.; Anttila, S.; Karjalainen, A.; Vainio, H.; Ristimaki, A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res., 1998, 58, 4997.
48. Hosomi, Y.; Yokose, T.; Hirose, Y.; Nakajima, R.; Nagai, K.; Nishiwaki, Y.; Ochiai, A. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adeno-carcinoma of the lung. Lung Cancer, 2000, 30, 73.
49. Huang, M.; Stolina, M.; Sharma, S.; Mao, J.; Zhu, L.; Miller, P.; Wollman, J.; Herschman, H.; Dubinett, S. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res., 1998, 58, 1208
50. Bouros, D.; Hatzakis, K.; Labrakis, H.; Zeibecoglou, K. Association of malignancy with diseases causing interstitial pulmonary changes. Chest, 2002, 121, 1278.
51. Hillerdal, G.; Henderson, D.W. Asbestos, asbestosis, pleural plaques and lung cancer. Scand. J. Work Environ. Health, 1997, 23, 93.
52. Achiwa, H.; Yatabe, Y.; Hida, T.; Kuroishi, T.; Kozaki, K.; Nakamura, S.; Ogawa, M.; Sugiura, T.; Mitsudomi, T.; Takahashi, T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res., 1999, 5, 1001.
53. Brabender, J.; Park, J.; Metzger, R.; Schneider, P.M.; Lord, R.V.; Holscher, A.H.; Danenberg, K.D.; Danenberg, P.V. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann. Surg., 2002, 235, 440.
54. Hasturk, S.; Kemp, B.; Kalapurakal, S.K.; Kurie, J.M.; Hong, W.K.; Lee, J.S. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer, 2002, 94, 1023.
55. Soslow, R.A.; Dannenberg, A.J.; Rush, D.; Woerner, B.M.; Khan, K.N.; Masferrer, J.; Koki, A.T. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer, 2000, 89, 2637.
56. Khuri, F.R.; Wu, H.; Lee, J.J.; Kemp, B.L.; Lotan, R.; Lippman, S.M.; Feng, L.; Hong, W.K.; Xu, X.-C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res., 2001, 7, 861.
57. Kim, H.S.; Youm, H.R.; Lee, J.S.; Min, K.W.; Chung, J.H.; Park, C.S. Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer, 2003, 42, 163.
58. West, H.; Yaziji, H.; Giarrita, S.; Livingston, R.; Vallieres, E.; Wood, D.; Gown, A. Cyclooxygenase-2 (COX-2) overexpression by immunohistochemistry (IHC) is associated with more aggressive biologic behavior of non-small cell lung cancer (NSCLC) tumors. ASCO, 2002, 21, 1235.
59. Campa, D.; Zienolddiny, S.; Maggini, V.; Skaug, V.; Haugen, A.; Canzian, F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis, 2004, 25, 229.
60. Schreinemachers, D.M.; Everson, R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 1994, 5, 138.
61. Tsujii, M.; DuBois, R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 1995, 83,493.
62. Krysan, K.; Dalwadi, H.; Sharma, S.; Pold, M.; Dubinett, S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res., 2004, 64, 6359.
63. Gately, S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev., 2000, 19, 19.
64. Leahy, K.; Koki, A.; Masferrer, J. Role of cyclooxygenases in angiogenesis. Curr. Med. Chem., 2000, 7, 1163.
65. Masferrer, J.L.; Leahy, K.M.; Koki, A.T. Role of cyclooxygenases in angiogenesis. Curr. Med. Chem., 2000, 7, 1163.
66. Stolina, M.; Sharma, S.; Lin, Y.; Dohadwala, M.; Gardner, B.; Luo, J.; Zhu, L.; Kronenberg, M.; Miller, P.W.; Portanova, J.; Lee, J.C.; Dubinett, S.M. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol., 2000, 164, 361.
67. Baratelli, F.; Lin, Y.; Zhu, L.; Yang, S.C.; Heuze-Vourc'h, N.; Zeng, G.; Reckamp, K.; Dohadwala, M.; Sharma, S.; Dubinett, S.M. PGE2 incudes FOXP3 gene expression and T regulatory function in human CD4+ T cells. J. Immunol., 2005, 173, 5458.
68. Dohadwala, M.; Luo, J.; Zhu, L.; Lin, Y.; Dougherty, G.; Sharma, S.; Huang, M.; Pold, M.; Batra, R.; Dubinett, S. Non small cell lung cancer cylooxygenase-2-dependent invasion is mediated by CD44. J. Biol. Chem., 2001, 276, 20809.
69. Subbaramaiah, K.; Altorki, N.; Chung, W.J.; Mestre, J.R.; Sampat, A.; Dannenberg, A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem., 1999, 274, 10911.
70. Subbaramaiah, K.; Telang, N.; Ramonetti, J.T.; Araki, R.; DeVito, B.; Weksler, B.B.; Dannenberg, A.J. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res., 1996, 56, 4424.
71. Bissonnette, M.; Khare, S.; von Lintig, F.C.; Wali, R.K.; Nguyen, L.; Zhang, Y.; Hart, J.; Skarosi, S.; Varki, N.; Boss, G.R.; Brasitus, T.A. Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: Effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1. Cancer Res., 2000, 60, 4602.
72. Fujita, M.; Fukui, H.; Kusaka, T.; Morita, K.; Fujii, S.; Ueda, Y.; Chiba, T.; Sakamoto, C.; Kawamata, H.; Fujimori, T. Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas. J. Gastroenterol. Hepatol., 2000, 15, 1277.
73. Gilhooly, E.; Rose, D. The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int. J. Oncol., 1999, 15, 267.
74. Berg, D.; Zhang, J.; Lauricella, D.; Moore, S. IL-10 is a central regulator of cyclooxygenase-2 expression and prostaglandin production. J. Immunol., 2001, 166, 2674.
75. Heuze-Vourc'h, N.; Zhu, L.; Krysan, K.; Batra, R.K.; Sharma, S.; Dubinett, S.M. Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells. Cancer Res., 2003, 63, 766.
76. 2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J. Immunol., 1996, 157, 5512.
77. Huang, M.; Wang, J.; Lee, P.; Sharma, S.; Mao, J.T.; Meissner, H.; Uyemura, K.; Modlin, R.; Wollman, J.; Dubinett, S.M. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res., 1995, 55, 3847.
78. Neuner, A.; Schindel, M.; Wildenberg, U.; Muley, T.; Lahm, H.; Fischer, J.R. Cytokine secretion: Clinical relevance of immunosuppression in non-small cell lung cancer. Lung Cancer, 2001, 34, S79.
79. Alleva, D.G.; Burger, C.J.; Elgert, K.D. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production: Role of tumor-derived IL-10, TGF-beta and prostaglandin E2. J. Immunol., 1994, 153, 1674.
80. D'Andrea, A.; Aste-Amezaga, M.; Valiante, N.M.; Ma, X.; Kubin, M.; Trinchieri, G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med., 1993, 178, 1041.
81. Wu, C.-Y.; Demeure, C.; Kiniwa, M.; Gately, M.; Delespesse, G. IL-12 induces the production of IFN-γ by neonatal human CD4 T cells. J. Immunol., 1993, 151, 1938.
82. Hagenbaugh, A.; Sharma, S.; Dubinett, S.; Wei, S.H.-Y.; Aranda, R.; Cheroutre, H.; Fowell, D.; Binder, S.; Tsao, B.; Locksley, R.; Moore, K.; Kronenberg, M. Altered immune responses in IL-10 transgenic mice. J. Exp. Med., 1997, 185, 2101.
83. Halak, B.K.; Maguire, H.C. Jr.; Lattime, E.C. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res., 1999, 59, 911.
84. Kim, J.; Modlin, R.L.; Moy, R.L.; Dubinett, S.M.; McHugh, T.; Nickoloff, B.J.; Uyemura, K. IL-10 production in cutaneous basal and squamous cell carcinomas: A mechanism for evading the local T cell immune response. J. Immunol., 1995, 155, 2240.
85. Sharma, S.; Stolina, M.; Lin, Y.; Gardner, B.; Miller, P.W.; Kronenberg, M.; Dubinett, S.M. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol., 1999, 163, 5020.
86. Hatanaka, H.; Abe, Y.; Naruke, M.; Tokunaga, T.; Oshika, Y.; Kawakami, T.; Osada, H.; Nagata, J.; Kamochi, J.; Tsuchida, T.; Kijima, H.; Yamazaki, H.; Inoue, H.; Ueyama, Y.; M., N. Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer. Clin. Cancer Res., 2001, 7, 1287.
87. De Vita, F.; Orditura, M.; Galizia, G.; Romano, C.; Roscigno, A.; Lieto, E.; Catalano, G. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest, 2000, 117, 365.
88. Hatanaka, H.; Abe, Y.; Kamiya, T.; Morino, F.; Nagata, J.; Tokunaga, T.; Oshika, Y.; Suemizu, H.; Kijima, H.; Tsuchida, T.; Yamazaki, H.; Inoue, H.; Nakamura, M.; Ueyama, Y. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann. Oncol., 2000, 11, 815.
89. Naruke, M.; Abe, Y.; Hatanaka, H.; Ohnishi, Y.; Yamazaki, H.; Kijima, H.; Nakamura, M.; Ueyama, Y.; Kobayashi, K. Interleukin-10 expression is correlated with growth fraction in human non-small cell lung cancer xenografts. Int. J. Oncol., 2001, 18, 1213.
90. Bianchi, R.; Grohmann, U.; Belladonna, M.; Silla, S.; Fallarino, F.; Ayroldi, E.; Fioretti, M.; Puccetti, P. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J. Immunol., 1996, 157, 1589.
91. Colombo, M.; Vagliani, M.; Spreafico, F.; Parenza, M.; Chiodoni, C.; Melani, C.; Stoppacciaro, A. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res., 1996, 56, 2531.
92. Handel-Fernandez, M.E.; Ching, X.; Herbert, L.M.; Lopez, D.M. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-γ production in mammary tumor-bearing mice. J. Immunol., 1997, 158, 280.
93. Molina-Holgado, E.; Arevalo-Martin, A.; Ortiz, S.; Vela, J.M.; Guaza, C. Theiler's virus infection induces the expression of cyclooxygenase-2 in murine astrocytes: Inhibition by the anti-inflammatory cytokines interieukin-4 and interleukin-10. Neurosci. Lett., 2002, 324, 237.
94. Moore, K.W.; de Waal Malefyt, R.; Coffman, R.L.; O'Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol., 2001, 19, 683.
95. Pomini, F.; Caruso, A.; Challis, J.R. Interleukin-10 modifies the effects of interleukin-1 beta and tumor necrosis factor-alpha on the activity and expression of prostaglandin H synthase-2 and the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase in cultured term human villous trophoblast and chorion trophoblast cells. J. Clin. Endocrinol. Metab., 1999, 84, 4645.
96. Trombetta, E.S.; Mellman, I. Cell biology of antigen processing and Annu. Rev. Immunol., 2005, 23, 975.
97. Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature, 1998, 392, 245
98. Almand, B.; Resser, J.R.; Lindman, B.; Nadaf, S.; Clark, J.I.; Kwon, E.D.; Carbone, D.P.; Gabrilovich, D.I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res., 2000, 6, 1755.
99. Sombroek, C.C.; Stam, A.G.; Masterson, A.J.; Lougheed, S.M.; Schakel, M.J.; Meijer, C.J.; Pinedo, H.M.; van den Eertwegh, A.J.; Scheper, R.J.; de Gruijl, T.D. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol., 2002, 168, 4333.
100. Yang, L.; Yamagata, N.; Yadav, R.; Brandon, S.; Courtney, R.L.; Morrow, J.D.; Shyr, Y.; Boothby, M.; Joyce, S.; Carbone, D.P.; Breyer, R.M. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest., 2003, 111, 727.
101. Sharma, S.; Stolina, M.; Yang, S.C.; Baratelli, F.; Lin, J.F.; Atianzar, K.; Luo, J.; Zhu, L.; Lin, Y.; Huang, M.; Dohadwala, M.; Batra, R.K.; Dubinett, S.M. Tumor Cyclooxygenase 2-dependent Suppression of Dendritic Cell Function. Clin. Cancer Res., 2003, 9, 961.
102. Mustelin, T.; Tasken, K. Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem. J., 2003, 371,15.
103. Shevach, E.M. CD4+ CD25+ suppressor T cells: More questions than answers. Nat. Rev. Immunol., 2002, 2, 389.
104. Sakaguchi, S.; Sakaguchi, N.; Shimizu, J.; Yamazaki, S.; Sakihama, T.; Itoh, M.; Kuniyasu, Y.; Nomura, T.; Toda, M.; Takahashi, T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev., 2001, 182,18.
105. Hori, S.; Nomura, T.; Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science, 2003, 299, 1057.
106. Sharma, S.; Yang, S.C.; Zhu, L.; Reckamp, K.; Gardner, B.; Baratelli, F.; Huang, M.; Batra, R.K.; Dubinett, S.M. Tumor Cyclooxygeanse-2/ Prostaglandin E2-Dependent Promotion of FOXP3 Expression and CD4+CD25+ T Regulatory Cell Activities in Lung Cancer. Cancer Res., 2005, 65, 5211.
107. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1995, 1, 27.
108. D'Amico, T.A.; Massey, M.; Herndon, J.E., 2nd, Moore, M.B.; Harpole, D.H. Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J. Thorac. Cardiovasc. Surg., 1999, 117, 736.
109. Dazzi, C.; Cariello, A.; Maioli, P.; Solaini, L.; Scarpi, E.; Rosti, G.; Lanzanova, G.; Marangolo, M. Prognostic and predictive value of intratumoral microvessel density in operable non-small-cell lung cancer. Lung Cancer, 1999, 24, 81.
110. Duarte, I.G.; Bufkin, B.L.; Pennington, M.F.; Gal, A.A.; Cohen, C.; Kosinski, A.S.; Mansour, K.A.; Miller, J.I. Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg., 1998, 115, 652.
111. Fontanini, G.; Bigini, D.; Vignati, S.; Basolo, F.; Mussi, A.; Lucchi, M.; Chine, S.; Angeletti, C.A.; Harris, A.L.; Bevilacqua, G. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J. Pathol., 1995, 177, 57.
112. Giatromanolaki, A.; Koukourakis, M.; O'Byrne, K.; Fox, S.; Whitehouse, R.; Talbot, D.C.; Harris, A.L.; Gatter, K.C. Prognostic value of angiogenesis in operable non-small cell lung cancer. J. Pathol., 1996, 179, 80.
113. Guddo, F.; Fontanini, G.; Reina, C.; Vignola, A.M.; Angeletti, A.; Bonsignore, G. The expression of basic fibroblast growth factor (bFGF) in tumor- associated stromal cells and vessels is inversely correlated with non- small cell lung cancer progression. Hum. Pathol., 1999, 30, 788.
114. Ohta, Y.; Shridhar, V.; Bright, R.K.; Kalemkerian, G.P.; Du, W.; Carbone, M.; Watanabe, Y.; Pass, H.I. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer, 1999, 81, 54.
115. Wikstrom, P.; Stattin, P.; Franck-Lissbrant, I.; Damber, J.E.; Bergh, A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate, 1998, 37, 19.
116. Pold, M.; Zhu, L.X.; Sharma, S.; Burdick, M.D.; Lin, Y.; Lee, P.P.; Pold, A.; Luo, J.; Krysan, K.; Dohadwala, M.; Mao, J.T.; Batra, R.K.; Strieter, R.M.; Dubinett, S.M. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/ CXCL8 in human non-small cell lung cancer. Cancer Res., 2004, 64, 1853.
117. Ambs, S.; Bennett; W.P.; Merriam, W.G.; Ogunfusika, M.O.; Oser, S.M.; Khan, M.A.; Jones, R.T.; Harris, C.C. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br. J. Cancer, 1998, 78, 233.
118. Konishi, T.; Huang, C.L.; Adachi, M.; Taki, T.; Inufusa, H.; Kodama, K.; Kohno, N.; Miyake, M. The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers. Int. J. Oncol., 2000, 16, 501.
119. Ravi, R.; Mookerjee, B.; Bhujwalla, Z.M.; Sutter, C.H.; Artemov, D.; Zeng, Q.; Dillehay, L.E.; Madan, A.; Semenza, G.L.; Bedi, A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev., 2000, 14, 34.
120. Jones, M.K.; Wang, H.; Peskar, B.M.; Levin, E.; Itani, R.M.; Sarfeh, I.J.; Tarnawski, A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med., 1999, 5, 1418.
121. Tsujii, M.; Kawano, S.; Tsuji, S.; Sawaoka, H.; Hori, M.; DuBois, R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 1998, 93, 705.
122. Williams, C.S.; Tsujii, M.; Reese, J.; Dey, S.K.; DuBois, R.N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest., 2000, 105, 1589.
123. Masferrer, J.L.; Leahy, K.M.; Koki, A.T.; Zweifel, B.S.; Settle, S.L.; Woerner, B.M.; Edwards, D.A.; Flickinger, A.G.; Moore, R.J.; Seibert, K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res., 2000, 60, 1306.
124. Marrogi, A.; Pass, H.I.; Khan, M.; Metheny-Barlow, L.J.; Harris, C.C.; Gerwin, B.I. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): antiproliferative effects of a COX-2 inhibitor. Cancer Res., 2000, 60, 3696.
125. Ermert, L.; Dierkes, C.; Ermert, M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin. Cancer Res., 2003, 9, 1604.
126. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100, 57.
127. Kinzler, K.W.; Vogelstein, B. Landscaping the cancer terrain. Science, 1998, 280, 1036.
128. Leahy, K.M.; Omberg, R.L.; Wang, Y.; Zweifel, B.S.; Koki, A.T.; Masferrer, J.L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells. Cancer Res., 2002, 62, 625.
129. Daniel, T.O.; Liu, H.; Morrow, J.D.; Crews, B.C.; Marnett, L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res., 1999, 59, 4574.
130. Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Metastasis: Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer, 2002, 2, 563.
131. Bartolazzi, A.; Peach, R.; Aruffo, A.; Stamenkovic, I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J. Exp. Med., 1994, 180, 53.
132. Yu, Q.; Stamenkovic, I. Cell surface-localized matrix metalloprotemase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev., 2000, 14, 163.
133. Dohadwala, M.; Batra, R.K.; Luo, J.; Lin, Y.; Krysan, K.; Pold, M.; Sharma, S.; Dubinett, S.M. Autocrine/paracrine prostaglandin E2 production by non-sm cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J. Biol. Chem., 2002, 277, 50828.
134. Yu, Q.; Stamenkovic, I. Localization of matrix metalloprotemase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev., 1999, 13, 35.
135. Shankavaram, U.T.; Lai, W.C.; Netzel-Arnett, S.; Mangan, P.R.; Ardans, J.A.; Caterina, N.; Stetler-Stevenson, W.G.; Birkedal-Hansen, H.; Wahl, L.M. Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J. Biol. Chem., 2001, 276, 19027.
136. Kozaki, K.; Koshikawa, K.; Tatematsu, Y.; Miyaishi, O.; Saito, H.; Hida, T.; Osada, H.; Takahashi, T. Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis. Oncogene, 2001, 20, 4228.
137. Pyke, C.; Romer, J.; Kallunki, P.; Lund, L.R.; Ralfkiaer, E.; Dano, K.; Tryggvason, K. The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am. J. Pathol., 1994, 145, 782.
138. Pyke, C.; Salo, S.; Ralfkiaer, E.; Romer, J.; Dano, K.; Tryggvason, K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res., 1995, 55, 4132.
139. Skyldberg,B.; Salo, S.; Eriksson, E.; Aspenblad, U.; Moberger, B.; Tryggvason, K.; Auer, G. Laminin-5 as a marker of invasiveness in cervical lesions. J. Natl. Cancer. Inst., 1999, 91, 1882.
140. Niki, T.; Kohno, T.; Iba, S.; Moriya, Y.; Takahashi, Y.; Saito, M.; Maeshima, A.; Yamada, T.; Matsuno, Y.; Fukayama, M.; Yokota, J.; Hirohashi, S. Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. Am. J. Pathol., 2002, 160, 1129.
141. Thiery, J.P. Epithelial-mesenchymal transitions in turnout progression. Nat. Rev. Cancer, 2002, 2, 442.
142. Takeichi, M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science, 1991, 251, 1451.
143. Fujita, Y.; Krause, G.; Scheffner, M.; Zechner, D.; Leddy, H.E.; Behrens, J.; Sommer, T.; Birchmeier, W. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat. Cell Biol., 2002, 4, 222.
144. Cano, A.; Perez-Moreno, M.A.; Rodrigo, I.; Locascio, A.; Blanco, M.J.; del Barrio, M.G.; Portillo, F.; Nieto, M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol., 2000, 2, 76.
145. Schulze, A.; Lehmann, K.; Jefferies, H.B.; McMahon, M.; Downward, J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev., 2001, 15, 981.
146. Hazzalin, C.A.; Mahadevan, L.C. MAPK-regulated transcription: A continuously variable gene switch? Nat. Rev. Mol. Cell. Biol., 2002, 3, 30.
147. Bhalla, U.S.; Iyengar, R. Emergent properties of networks of biologal signaling pathways. Science, 1999, 283, 381.
148. Rozengurt, E. Neuropeptides as growth factors for normal and cancerous cells. Trends Endocrinol. Metab., 2002, 13, 128.
149. Baxter, R.C. Signalling pathways involved in antiproliferative effects of IGFBP-3: A review. Mol. Pathol., 2001, 54, 145.
150. Foulstone, E.; Prince, S.; Zaccheo, O.; Burns, J.L.; Harper, J.; Jacobs, C.; Church, D.; Hassan, A.B. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J. Pathol., 2005, 205, 145.
151. Pold, M.; Krysan, K.; Pold, A.; Dohadwala, M.; Heuze-Vourc'h, N.; Mao, J.T.; Riedl, K.L.; Sharma, S.; Dubinett, S.M. Cyclooxygenase-2 Modulates the Insulin-Like Growth Factor Axis in Non-Small-Cell Lung Cancer. Cancer Res., 2004, 64, 6549.
152. Ferreira, C.G.; Epping, M.; Kruyt, F.A.; Giaccone, G. Apoptosis: Target of cancer therapy. Clin. Cancer Res., 2002, 8, 2024.
153. Liu, X.H.; Yao, S.; Kirschenbaum, A.; Levine, A.C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and downregulates bcl-2 expression in LNCaP cells. Cancer Res., 1998, 58, 4245.
154. 2 in human colon cancer cells. Cancer Res., 1998, 58, 362.
155. Lin, M.T.; Lee, R.C.; Yang, P.C.; Ho, F.M.; Kuo, M.L. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem., 2001, 276, 48997.
156. Chang, Y.W.; Jakobi, R.; McGinty, A.; Foschi, M.; Dunn, MJ.; Sorokin, A. Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol. Cell. Biol., 2000, 20, 8571.
157. Hsu, A.L.; Ching, T.T.; Wang, D.S.; Song, X.; Rangnekar, V.M.; Chen, C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bc1-2. J. Biol. Chem., 2000, 275, 11397.
158. Erickson, B.A.; Longo, W.E.; Panesar, N.; Mazuski, J.E.; Kaminski, D.L. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J. Surg. Res., 1999, 81, 101.
159. Hara, A.; Yoshimi, N.; Niwa, M.; Ino, N.; Mori, H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn. J. Cancer Res., 1997, 88, 600.
160. Sawaoka, H.; Kawano, S.; Tsuji, S.; Tsujii, M.; Gunawan, E.S.; Takei, Y.; Nagano, K.; Hori, M. Cyclooxygenase-2 inhibitors suppress the growth
161. Chang, H.C.; Weng, C.F. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol. Rep., 2001, 8, 1321.
162. Hida, T.; Kozaki, K.; Muramatsu, H.; Masuda, A.; Shimizu, S.; Mitsudomi, T.; Sugiura, T.; Ogawa, M.; Takahashi, T. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res., 2000, 6, 2006.
163. Yao, R.; Rioux, N.; Castonguay, A.; You, M. Inhibition of COX-2 and induction of apoptosis: Two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Exp. Lung Res., 2000, 26, 731.
164. Krysan, K.; Merchant, F.H.; Zhu, L.; Dohadwala, M.; Luo, J.; Lin, Y.; Heuze-Vourc'h, N.; Pold, M.; Seligson, D.; Chia, D.; Goodglick, L.; Wang, H.; Strieter, R.; Sharma, S.; Dubinett, S. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J., 2004, 18, 206.
165. Krysan, K.; Dalwadi, H.; Sharma, S.; Pold, M.; Dubinett, S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res., 2004, 64, 6359.
166. Dannenberg, A.J.; Altorki, N.K.; Boyle, J.O.; Lin, D.T.; Subbaramaiah, K. Inhibition of cyclooxygenase-2: An approach to preventing cancer of the upper aerodigestive tract. Ann. N Y Acad. Sci., 2001, 952, 109.
167. Elder, D.J.; Halton, D.E.; Hague, A.; Paraskeva, C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res., 1997, 3, 1679.
168. Hsueh, C.T.; Chiu, C.F.; Kelsen, D.P.; Schwartz, G.K. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. Cancer Chemother. Pharmacol., 2000, 45, 389.
169. Subbaramaiah, K.; Hart, J.C.; Norton, L.; Dannenberg, A.J. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J. Biol Chem., 2000, 275, 14838.
170. Milas, L.; Furuta, Y.; Hunter, N.; Nishiguchi, I.; Runkel, S. Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence. Cancer Res., 1990, 50, 4473.
171. Milas, L.; Kishi, K.; Hunter, N.; Mason, K.; Masferrer, J.L.; Tofilon, P.J. Enhancement of Tumor Response to gamma-Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme. J. Natl. Cancer Inst., 1999, 91, 1501.
172. Pyo, H.; Choy, H.; Amorino, G.P.; Kim, J.S.; Cao, Q.; Hercules, S.K.; DuBois, R.N. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation and preferentially on the cells that express cyclooxygenase-2. Clin. Cancer Res., 2001, 7, 2998.
173. Hung, W.C.; Chang, H.C.; Pan, M.R.; Lee, T.H.; Chuang, L.Y. Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol. Pharmacol., 2000, 58, 1398.
174. Thun, M.J.; Henley, S.J.; Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst., 2002 94, 252.
175. DuBois, R.; Shao, J.; Tsujii, M.; Sheng, H.; Beauchamp, R. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res., 1996, 56, 733.
176. Shiff, S.J.; Qiao, L.; Tsai, L.L.; Rigas, B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest., 1995, 96, 491.
177. Hawk, E.T.; Viner, J.L.; Dannenberg, A.; DuBois, R.N. COX-2 in cancer - a player that's defining the rules. J. Natl. Cancer Inst., 2002, 94, 545.
178. Hwang, D.H.; Fung, V.; Dannenberg, A.J. National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: Role of COX-dependent and -independent mechanisms. Neoplasia, 2002, 4, 91.
179. Song, X.; Lin, H.P.; Johnson, A.J.; Tseng, P.H.; Yang, Y.T.; Kulp, S.K.; Chen, C.S. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst., 2002, 94, 585.
180. Sanchez-Alcazar, J.A.; Bradbury, D.A.; Pang, L.; Knox, A.J. Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways. Lung Cancer, 2003, 40, 33.
181. Grosch, S.; Tegeder, I.; Niederberger, E.; Brautigam, L.; Geisslinger, G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J., 2001, 15, 2742.
182. Altorki, N.K.; Keresztes, R.S.; Port, J.L.; Libby, D.M.; Korst, R.J.; Flieder, D.B.; Ferrara, C.A.; Yankelevitz, D.F.; Subbaramaiah, K.; Pasmantier, M.W.; Dannenberg, A.J. Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J. Clin. Oncol., 2003, 21, 2645.
183. Csiki, I.; Morrow, J.D.; Sandler, A.; Shyr, Y.; Oates, J.; Williams, M.K.; Dang, T.; Carbone, D.P.; Johnson, D.H. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: A phase II trial of celecoxib and docetaxel. Clin. Cancer Res., 2005, 11, 6634.